46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Phase Variable Expression of Capsular Polysaccharide Modifications Allows Campylobacter jejuni to Avoid Bacteriophage Infection in Chickens

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bacteriophages are estimated to be the most abundant entities on earth and can be found in every niche where their bacterial hosts reside. The initial interaction between phages and Campylobacter jejuni, a common colonizer of poultry intestines and a major source of foodborne bacterial gastroenteritis in humans, is not well understood. Recently, we isolated and characterized a phage F336 resistant variant of C. jejuni NCTC11168 called 11168R. Comparisons of 11168R with the wildtype lead to the identification of a novel phage receptor, the phase variable O-methyl phosphoramidate (MeOPN) moiety of the C. jejuni capsular polysaccharide (CPS). In this study we demonstrate that the 11168R strain has gained cross-resistance to four other phages in our collection (F198, F287, F303, and F326). The reduced plaquing efficiencies suggested that MeOPN is recognized as a receptor by several phages infecting C. jejuni. To further explore the role of CPS modifications in C. jejuni phage recognition and infectivity, we tested the ability of F198, F287, F303, F326, and F336 to infect different CPS variants of NCTC11168, including defined CPS mutants. These strains were characterized by high-resolution magic angle spinning NMR spectroscopy. We found that in addition to MeOPN, the phase variable 3- O-Me and 6- O-Me groups of the NCTC11168 CPS structure may influence the plaquing efficiencies of the phages. Furthermore, co-infection of chickens with both C. jejuni NCTC11168 and phage F336 resulted in selection of resistant C. jejuni bacteria, which either lack MeOPN or gain 6- O-Me groups on their surface, demonstrating that resistance can be acquired in vivo. In summary, we have shown that phase variable CPS structures modulate phage infectivity in C. jejuni and suggest that the constant phage predation in the avian gut selects for changes in these structures leading to a continuing phage–host co-evolution.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences.

          Campylobacter jejuni, from the delta-epsilon group of proteobacteria, is a microaerophilic, Gram-negative, flagellate, spiral bacterium-properties it shares with the related gastric pathogen Helicobacter pylori. It is the leading cause of bacterial food-borne diarrhoeal disease throughout the world. In addition, infection with C. jejuni is the most frequent antecedent to a form of neuromuscular paralysis known as Guillain-Barré syndrome. Here we report the genome sequence of C. jejuni NCTC11168. C. jejuni has a circular chromosome of 1,641,481 base pairs (30.6% G+C) which is predicted to encode 1,654 proteins and 54 stable RNA species. The genome is unusual in that there are virtually no insertion sequences or phage-associated sequences and very few repeat sequences. One of the most striking findings in the genome was the presence of hypervariable sequences. These short homopolymeric runs of nucleotides were commonly found in genes encoding the biosynthesis or modification of surface structures, or in closely linked genes of unknown function. The apparently high rate of variation of these homopolymeric tracts may be important in the survival strategy of C. jejuni.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Bacteriophages as potential new therapeutics to replace or supplement antibiotics.

            Over recent decades, a growing body of literature has validated the use of bacteriophages for therapy and prophylaxis in the war against drug-resistant bacteria. Today, much more is known about bacteriophages than in the 1930s when phage therapy first appeared and began to spread to many countries. With rapid dissemination of multi-drug-resistant bacterial pathogens, the interest in alternative remedies to antibiotics, including bacteriophage treatments, is gaining new ground. Based on recent experience and current results of bacteriophage applications against bacterial infections in countries where this alternative therapy is approved, many scientists and companies have come to believe that the use of phages for treating and preventing bacterial diseases will be successful. Copyright © 2010 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Linking genetic change to community evolution: insights from studies of bacteria and bacteriophage

                Bookmark

                Author and article information

                Journal
                Front Cell Infect Microbiol
                Front Cell Infect Microbiol
                Front. Cell. Inf. Microbio.
                Frontiers in Cellular and Infection Microbiology
                Frontiers Research Foundation
                2235-2988
                20 February 2012
                2012
                : 2
                : 11
                Affiliations
                [1] 1simpleDepartment of Veterinary Disease Biology, University of Copenhagen Frederiksberg, Denmark
                [2] 2simpleDepartment of Biological Sciences, Alberta Glycomics Centre, University of Alberta Edmonton, AB, Canada
                [3] 3simpleNational Food Institute, Technical University of Denmark Søborg, Denmark
                Author notes

                Edited by: Alain Stintzi, Ottawa Institute of Systems Biology, Canada

                Reviewed by: Jun Lin, The University of Tennessee, USA; Duncan Maskell, University of Cambridge, UK

                *Correspondence: Christine M. Szymanski, Department of Biological Sciences, Alberta Glycomics Centre, University of Alberta, Edmonton, AB, Canada T6G 2E9. e-mail: christine.szymanski@ 123456ualberta.ca ; Lone Brøndsted, Department of Veterinary Disease Biology, University of Copenhagen, Stigbøjlen 4, DK-1879 Frederiksberg C, Denmark. e-mail: lobr@ 123456life.ku.dk

                Martine C. Holst Sørensen and Lieke B. van Alphen have contributed equally to this work.

                Article
                10.3389/fcimb.2012.00011
                3417653
                22919603
                8757eaee-5e24-4fe2-9c09-6a83745129d4
                Copyright © 2012 Sørensen, van Alphen, Fodor, Crowley, Christensen, Szymanski and Brøndsted.

                This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

                History
                : 02 November 2011
                : 30 January 2012
                Page count
                Figures: 4, Tables: 5, Equations: 0, References: 43, Pages: 11, Words: 7660
                Categories
                Microbiology
                Original Research

                Infectious disease & Microbiology
                phosphoramidate,phase variation,bacteriophage,methylation,campylobacter jejuni,capsular polysaccharide

                Comments

                Comment on this article